JP2009510129A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510129A5
JP2009510129A5 JP2008533792A JP2008533792A JP2009510129A5 JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5 JP 2008533792 A JP2008533792 A JP 2008533792A JP 2008533792 A JP2008533792 A JP 2008533792A JP 2009510129 A5 JP2009510129 A5 JP 2009510129A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
agent
modulator
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2008533792A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510129A (ja
JP5517454B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/038823 external-priority patent/WO2007041632A2/en
Publication of JP2009510129A publication Critical patent/JP2009510129A/ja
Publication of JP2009510129A5 publication Critical patent/JP2009510129A5/ja
Application granted granted Critical
Publication of JP5517454B2 publication Critical patent/JP5517454B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2008533792A 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物 Expired - Fee Related JP5517454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72267905P 2005-09-30 2005-09-30
US60/722,679 2005-09-30
US78754906P 2006-03-29 2006-03-29
US60/787,549 2006-03-29
PCT/US2006/038823 WO2007041632A2 (en) 2005-09-30 2006-10-02 Methods and pharmaceutical compositions for the treatment and prevention of hepatitis c infection

Publications (3)

Publication Number Publication Date
JP2009510129A JP2009510129A (ja) 2009-03-12
JP2009510129A5 true JP2009510129A5 (OSRAM) 2009-11-19
JP5517454B2 JP5517454B2 (ja) 2014-06-11

Family

ID=37906852

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533792A Expired - Fee Related JP5517454B2 (ja) 2005-09-30 2006-10-02 Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物

Country Status (13)

Country Link
US (1) US7754685B2 (OSRAM)
EP (1) EP1933859A2 (OSRAM)
JP (1) JP5517454B2 (OSRAM)
KR (1) KR20080059270A (OSRAM)
CN (1) CN105169369B (OSRAM)
AU (1) AU2006299426B2 (OSRAM)
BR (1) BRPI0616476A2 (OSRAM)
CA (1) CA2623865A1 (OSRAM)
IL (1) IL190478A0 (OSRAM)
NZ (1) NZ567262A (OSRAM)
RU (1) RU2440822C2 (OSRAM)
WO (1) WO2007041632A2 (OSRAM)
ZA (1) ZA200803493B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583494C (en) * 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
DE602006020152D1 (de) * 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
KR20080059270A (ko) 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
CN101511357B (zh) 2006-05-19 2011-11-02 西尼克斯公司 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
CA2659461A1 (en) * 2006-08-25 2008-02-28 Wyeth Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) * 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
CN101815533A (zh) 2007-05-04 2010-08-25 弗特克斯药品有限公司 用于治疗hcv感染的组合治疗
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
KR101068160B1 (ko) * 2008-12-30 2011-09-27 건국대학교 산학협력단 Ｃ형 간염 바이러스 ｒｎａ핵산 중합효소의 활성을 저해하는 신규 플라보놀 유도체
CA2748389A1 (en) * 2008-12-31 2010-07-08 Scynexis, Inc. Derivatives of cyclosporin a
MX2011007194A (es) * 2009-01-07 2013-07-12 Scynexis Inc Combinacion de un derivado ciclosporina y nucleosidos para tratar virus de hepatitis c (vhc).
US20120301463A1 (en) 2009-09-30 2012-11-29 President And Fellows Of Harvard College Methods for Modulation of Autophagy Through the Modulation of Autophagy-Enhancing Gene Products
AU2012285973A1 (en) 2011-07-15 2014-01-30 Basf Se Pesticidal methods using substituted 3-pyridyl thiazole compounds and derivatives for combating animal pests I
RU2639388C1 (ru) * 2016-10-11 2017-12-21 Федеральное государственное бюджетное учреждение "Государственный научный центр "Институт иммунологии" Федерального медико-биологического агентства России Композиция для терапии вирусного гепатита С
WO2020037530A1 (en) * 2018-08-22 2020-02-27 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Crystalline form of compound and uses thereof in medicine
AU2021256222A1 (en) * 2020-04-15 2022-10-06 Farsight Medical Technology (Shanghai) Co., Ltd. Prevention and treatment of organ injuries

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022896A1 (fr) * 1993-03-31 1994-10-13 Tokyo Tanabe Company Limited Ameliorant de la cholestase
AU688344B2 (en) * 1993-07-19 1998-03-12 Mitsubishi-Tokyo Pharmaceuticals, Inc. Hepatitis C virus proliferation inhibitor
CN1141317C (zh) * 1995-07-17 2004-03-10 碳化学公司 有抗人体免疫缺损病毒作用的环孢菌素衍生物
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757520B1 (fr) 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
DE69912952T2 (de) * 1998-06-12 2004-09-02 C-Chem Ag Cyclosporine
FR2780061B1 (fr) 1998-06-22 2001-09-07 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
AU759480B2 (en) 1998-07-01 2003-04-17 Debiopharm S.A. Novel cyclosporin with improved activity profile
DE69822814T2 (de) * 1998-08-18 2005-01-27 Panacea Biotec Ltd. Zusammensetzung enthaltend Cyclosporin in einem hydrophilen Träger
TR200103147T1 (tr) 1999-12-27 2002-06-21 Japan Tobacco Inc. Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı.
SI1385870T1 (sl) * 2000-07-21 2010-08-31 Schering Corp Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C
US7105499B2 (en) * 2001-01-22 2006-09-12 Merck & Co., Inc. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
NZ533628A (en) * 2001-11-27 2006-07-28 Anadys Pharmaceuticals Inc 3-beta-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and uses thereof
US6987090B2 (en) * 2002-05-09 2006-01-17 Lg Household & Health Care Ltd. Use of 3-position cyclosporin derivatives for hair growth
KR20040039622A (ko) 2002-11-04 2004-05-12 주식회사 엘지생활건강 모발 성장 효과를 갖는 사이클로스포린 3 위치 유도체를유효성분으로 하는 모발 성장 촉진제
MXPA04012802A (es) * 2002-06-28 2005-04-19 Idenix Cayman Ltd Ester 2'-c-metil-3'-o-l-valina de ribofuranosil-citidina para el tratamiento de infecciones por flaviviridae.
WO2005000308A2 (en) 2003-05-15 2005-01-06 Rigel Pharmaceuticals, Inc. Methods of identifying hcv ns5b polymerase inhibitors and use against hepatitis c
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
GB0320638D0 (en) * 2003-09-03 2003-10-01 Novartis Ag Organic compounds
ATE497775T1 (de) 2004-07-14 2011-02-15 Novartis Pharma Gmbh Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
US20060025267A1 (en) * 2004-07-29 2006-02-02 Mircea Gradu Differential with torque vectoring capabilities
CA2583494C (en) 2004-10-01 2014-01-21 Scynexis, Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
HRP20110169T1 (hr) * 2004-10-01 2011-04-30 Debiopharm S.A. Upotreba [d-meala]3-[etval]4-ciklosporina za liječenje infekcija hepatitisom c
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
KR20070087624A (ko) 2004-12-23 2007-08-28 노파르티스 아게 Ｈｃｖ 치료용 조성물
CN101084005A (zh) 2004-12-23 2007-12-05 诺瓦提斯公司 用于黄病毒科治疗的化合物
US7473688B2 (en) * 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
KR20080059270A (ko) 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
DE602006020152D1 (de) 2005-09-30 2011-03-31 Scynexis Inc Arylalkyl- und heteroarylalkyl-derivate von cyclosporin a bei der behandlung und vorbeugung einer virusinfektion
CN101511357B (zh) 2006-05-19 2011-11-02 西尼克斯公司 环孢菌素类化合物及其组合物在制备治疗和预防眼部疾病的药物中的应用
WO2008069917A2 (en) 2006-11-20 2008-06-12 Scynexis, Inc. Novel cyclic peptides
WO2008127613A1 (en) 2007-04-11 2008-10-23 Scynexis, Inc. New pharmaceutical compositions
WO2008143996A1 (en) 2007-05-18 2008-11-27 Scynexis, Inc. New chemical processes

Similar Documents

Publication Publication Date Title
JP2009510129A5 (OSRAM)
RU2008117157A (ru) Способы и фармацевтические композиции для лечения и профилактики инфекции гепатита с
JP5578853B2 (ja) ウイルス感染の治療のための化合物、及び医薬組成物
JP2013521279A5 (OSRAM)
ES2354282T3 (es) Análogos peptídicos inhibidores de la hepatitis c.
ES2290425T3 (es) Tripeptidos heterociclicos en calidad de inhibidores de la hepatitis c.
JP2010508361A5 (OSRAM)
JP5254964B2 (ja) 抗ウイルス剤としての大環状化合物
US6642204B2 (en) Hepatitis C inhibitor tri-peptides
JP2016503800A5 (OSRAM)
JP2013514359A5 (OSRAM)
JP2010509376A5 (OSRAM)
JP2012504632A5 (OSRAM)
JP2010508362A5 (OSRAM)
US20030186895A1 (en) Hepatitis C inhibitor tri-peptides
JP2014504643A5 (OSRAM)
ZA200405639B (en) Macrocyclic peptides active against the hepatitis C virus.
US20060089300A1 (en) Macrocyclic peptides active against the hepatitis C virus
JP2007535491A5 (OSRAM)
US20110218175A1 (en) Antiviral agents
AU2003202347A1 (en) Tripeptides having a hydroxyproline ether of a substituted quinoline for the inhibition of NS3 (Hepatitis C)
ZA200100972B (en) Hepatituis C inhibitor peptides.
US20050159345A1 (en) Composition for the treatment of infection by Flaviviridae viruses
JP2010508360A5 (OSRAM)
JP2012513479A5 (OSRAM)